Morphic Medical Achieves NUB Status One for RESET® Endoscopic Therapy in Germany

Morphic Medical Achieves Significant Milestone in Germany

Morphic Medical, the innovator behind the first medical device targeting the root causes of obesity and Type 2 diabetes, announced a groundbreaking achievement regarding its RESET® therapy in Germany. The therapy has recently been granted NUB Status One under the New Examination and Treatment Methods (NUB) framework, which is crucial for hospitals seeking reimbursement for innovative medical services.

What is RESET® Therapy?

RESET® represents a cutting-edge, minimally invasive endoscopic procedure designed to facilitate weight loss and enhance cardiometabolic health, specifically addressing conditions like Type 2 diabetes. The innovative approach is engineered to deliver immediate weight reduction and metabolic improvements without any surgical incisions, marking a significant development in the treatment landscape for patients battling obesity and metabolic disorders.

Significance of NUB Status One

The NUB Status One recognition is not merely a label; it lays the groundwork for broader reimbursement opportunities across German hospitals. By achieving this status, RESET® is now positioned to significantly improve its accessibility to patients, promoting comprehensive coverage for this essential medical procedure. Hospitals can apply for additional reimbursement, a move expected to widen the therapy's acceptance and expedite its commercial rollout.

According to Mike Gutteridge, the CEO of Morphic Medical, "The NUB recognition signifies an essential advancement for Morphic Medical and the patients and hospitals seeking evidence-based endoscopic metabolic therapies. The status is supported by a robust body of clinical evidence accumulated over years of research and practical experience, which is instrumental in facilitating reimbursement discussions with medical centers in Germany."

Clinical Foundation and Evidence

The decision to grant NUB Status One was grounded in extensive peer-reviewed publications, real-world data, and clinical experiences led by investigators, validating the safety, efficacy, durability, and metabolic benefits of therapies based on duodenal-jejunal bypass liners, specifically for individuals suffering from obesity and Type 2 diabetes. This comprehensive foundation offers confidence to both healthcare professionals and patients regarding the SHIFT®’s role as a clinically beneficial therapy.

Future Prospects and Collaborations

Following the acquisition of the NUB Status, Morphic Medical plans to collaborate with leading hospitals in Germany to support individual NUB applications and further expand clinical use. This partnership will focus on promoting long-term clinical observation alongside registry participation, as well as generating evidence that will support ongoing reimbursement and integration into medical guidelines.

About Morphic Medical

Founded in 2003 and headquartered in Boston, Massachusetts, Morphic Medical specializes in developing alternative non-surgical treatments for severe obesity and related cardiometabolic risk factors like Type 2 diabetes. It’s important to note that the RESET® is not approved for sale in the United States and is intended for research purposes under federal law. For more information, visit morphicmedical.com or follow them on social media platforms.

This milestone not only enhances Morphic Medical's profile in the healthcare landscape but also represents a crucial step forward for patients looking towards innovative solutions for obesity and Type 2 diabetes treatments.